ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintSite TitleTitle ChevronIcon Twitter
Health Technology

AnGes MG, Inc.

Business Summary

AnGes, Inc. engages in the research and development of gene-based medical products. It offers genetic medicines such as hepatocyte growth factor (HGF) genetic medicines, NF-KB decoy oligo and hemagglutinating virus of Japan envelope (HVJ-E) non-viral vector, and others. It is also involved in the research and development of medical equipment, which improves blood circulation by regenerating blood vessels and NfkB which controls various inflammations. The company was founded on December 17, 1999 and is headquartered in Ibaraki, Japan.

Financial Highlights

Dec 2019 JPYUSD
Revenue326.75M2.99M
Gross Profit235.16M2.15M
Operating income-3,270.00M-29.99M
Income before tax-3,751.60M-34.41M
Net income-3,750.82M-34.40M
EBITDA-3,262.68M-29.92M
Diluted EPS-35.81-0.32
Dividends Per Share00
Total Assets12,524.60M115.24M
Total liabilities469.24M4.31M
Total equity12,055.35M110.93M
Operating cash flow-2,179.91M-19.99M
Currency in JPYCurrency in USD

Historical Data

 Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019
Revenue 430.15M 514.26M 365.18M 610.05M 326.75M
Gross Profit 217.14M 281.91M 163.69M 418.87M 235.16M
Operating income -4,171.98M -4,615.47M -3,288.68M -3,065.25M -3,270.00M
Income before tax -4,124.15M -4,760.67M -3,744.18M -3,003.00M -3,751.60M
Net income -4,143.33M -4,776.78M -3,764.69M -2,996.62M -3,750.82M
EBITDA -4,123.00M -4,548.16M -3,259.32M -3,057.39M -3,262.68M
Diluted EPS -74.53 -75.29 -49.38 -34.46 -35.81
Dividends Per Share 0 0 0 0 0
Total Assets 4,765.68M 4,539.20M 3,963.60M 8,050.67M 12,524.60M
Total liabilities 544.33M 669.81M 341.72M 316.21M 469.24M
Total equity 4,221.35M 3,869.38M 3,621.88M 7,734.45M 12,055.35M
Operating cash flow -4,595.74M -4,983.69M -2,991.22M -2,522.50M -2,179.91M
 Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019
Revenue 3.55M 4.73M 3.25M 5.52M 2.99M
Gross Profit 1.79M 2.59M 1.45M 3.79M 2.15M
Operating income -34.46M -42.47M -29.32M -27.75M -29.99M
Income before tax -34.06M -43.81M -33.39M -27.19M -34.41M
Net income -34.22M -43.96M -33.57M -27.13M -34.40M
EBITDA -34.05M -41.85M -29.06M -27.68M -29.92M
Diluted EPS -0.61 -0.69 -0.44 -0.31 -0.32
Dividends Per Share 0 0 0 0 0
Total Assets 39.61M 38.91M 35.18M 73.37M 115.24M
Total liabilities 4.52M 5.74M 3.03M 2.88M 4.31M
Total equity 35.09M 33.17M 32.15M 70.49M 110.93M
Operating cash flow -37.96M -45.86M -26.67M -22.83M -19.99M

Valuation Measures

Dec 2019
PER--
ROA-36.45%
ROE-37.90%
Operating margin-1,000.73%
Profit margin-1,147.88%

Key executives

  • President & Representative Director: Ei Yamada
  • Executive Officer, Manager-R&D Promotion: Hajime Watanabe
  • Manager-Accounting: Jun Sakurai

Shareholders

  • Shionogi & Co., Ltd. (0.9%)
  • BlackRock Fund Advisors (0.8%)
  • ISOHATA TERUO (0.6%)
  • MORISHITA RYUICHI (0.5%)
  • BlackRock Advisors (UK) Ltd. (0.1%)
  • TIAA-CREF Investment Management LLC (0.0%)
  • SSgA Funds Management, Inc. (0.0%)
  • ISHIHARA SANGYO KAISHA LTD. (0.0%)
  • Credit Suisse Asset Management (Schweiz) AG (0.0%)
  • Handelsbanken Fonder AB (0.0%)

Contact Details

  • Website:http://www.anges.co.jp
  • Address: Saito Bio-Incubator 1F, 7-7-15 Saito-Asagi, Osaka, 567-0085, Japan
  • Phone: +81.72.643.3590

Related Companies

  • AnGes USA, Inc.
  • AnGes Euro Ltd.

Competitors

  • Sienna Biopharmaceuticals, Inc.
Last Updated on 4 Aug, 2020

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends July 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media